Evaluation of photoactivated chromophore for keratitis–corneal cross‐linking (PACK‐CXL) in feline infectious keratitis—patient demographics, treatment protocols, risk factors, and treatment outcome: a retrospective study

Abstract

AbstractObjectivesTo describe patient demographics and treatment protocols in a population of feline patients undergoing photoactivated chromophore for keratitis–corneal cross‐linking (PACK–CXL) as an adjunctive treatment for infectious keratitis. Furthermore, to determine the proportion of PACK–CXL treatment success in the population studied, explore risk factors for treatment failure, and provide recommendations for future PACK–CXL clinical studies.Materials and MethodsRecords from four veterinary ophthalmology practices were reviewed to identify eligible patients and extract data. Recorded variables included patient‐related factors, ocular examination findings, PACK‐CXL protocol parameters, and treatment outcome.ResultsRecords for 153 cats (154 eyes) were included. Median age in the treatment success group was 8 years (interquartile range (IQR) 4–12), with a median ulcer depth of 30% (IQR 30–40). Median age in the treatment failure group was 10.5 years (IQR 4.75–12) with a median ulcer depth of 45.9% (IQR 30–75). Persian cats were the most represented brachycephalic breed (52 out of 64 cats). Modified PACK–CXL protocols were used, including fast energy delivery (134 eyes), and increased fluence (52 eyes). The overall proportion of success was 88% (95% CI 84–93), which was variable between clinics. Eighty‐two of 89 mesocephalic cat eyes (92%), and 54 of 65 brachycephalic cat eyes (83%) were classified as treatment successes.ConclusionsPACK–CXL appeared to be a useful, adjunctive therapeutic modality for the treatment of infectious keratitis in the feline patient population presented here. Brachycephalic cats, older cats, and those with deeper ulcers may be at increased risk for treatment failure.